KR100806927B1 - 카르복실산, 그의 유도체 및 이들을 함유하는 약학적조성물 - Google Patents

카르복실산, 그의 유도체 및 이들을 함유하는 약학적조성물 Download PDF

Info

Publication number
KR100806927B1
KR100806927B1 KR1020077003601A KR20077003601A KR100806927B1 KR 100806927 B1 KR100806927 B1 KR 100806927B1 KR 1020077003601 A KR1020077003601 A KR 1020077003601A KR 20077003601 A KR20077003601 A KR 20077003601A KR 100806927 B1 KR100806927 B1 KR 100806927B1
Authority
KR
South Korea
Prior art keywords
delete delete
formula
carbon atoms
obesity
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077003601A
Other languages
English (en)
Korean (ko)
Other versions
KR20070026888A (ko
Inventor
제이콥 바-타나
Original Assignee
이쑴리서치디벨로프먼트컴파니오브더헤브류유니버시티오브예루살렘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이쑴리서치디벨로프먼트컴파니오브더헤브류유니버시티오브예루살렘 filed Critical 이쑴리서치디벨로프먼트컴파니오브더헤브류유니버시티오브예루살렘
Publication of KR20070026888A publication Critical patent/KR20070026888A/ko
Application granted granted Critical
Publication of KR100806927B1 publication Critical patent/KR100806927B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/602—Dicarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020077003601A 1997-01-07 1997-12-25 카르복실산, 그의 유도체 및 이들을 함유하는 약학적조성물 Expired - Fee Related KR100806927B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL119971 1997-01-07
IL11997197A IL119971A (en) 1997-01-07 1997-01-07 Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1019997006147A Division KR100806928B1 (ko) 1997-01-07 1997-12-25 카르복실산, 그의 유도체 및 이들을 함유하는 약학적 조성물

Publications (2)

Publication Number Publication Date
KR20070026888A KR20070026888A (ko) 2007-03-08
KR100806927B1 true KR100806927B1 (ko) 2008-02-22

Family

ID=11069666

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077003601A Expired - Fee Related KR100806927B1 (ko) 1997-01-07 1997-12-25 카르복실산, 그의 유도체 및 이들을 함유하는 약학적조성물
KR1019997006147A Expired - Fee Related KR100806928B1 (ko) 1997-01-07 1997-12-25 카르복실산, 그의 유도체 및 이들을 함유하는 약학적 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019997006147A Expired - Fee Related KR100806928B1 (ko) 1997-01-07 1997-12-25 카르복실산, 그의 유도체 및 이들을 함유하는 약학적 조성물

Country Status (10)

Country Link
US (3) US6284903B1 (enExample)
EP (2) EP2112134B1 (enExample)
JP (2) JP2001507713A (enExample)
KR (2) KR100806927B1 (enExample)
AT (1) ATE431816T1 (enExample)
AU (1) AU742945B2 (enExample)
CA (1) CA2277075C (enExample)
DE (1) DE69739415D1 (enExample)
IL (1) IL119971A (enExample)
WO (1) WO1998030530A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6814962B1 (en) * 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
IL119971A (en) * 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
JP2002541129A (ja) 1999-04-01 2002-12-03 エスペリオン セラピューティクス インコーポレイテッド エーテル化合物、組成物、およびそれらの使用
CN1479721A (zh) 2000-10-11 2004-03-03 ͨ��ҽ�ƹ�˾ 用于胆固醇治疗和相关应用的亚砜和双亚砜化合物和组合物
AU2002213136B2 (en) 2000-10-11 2007-01-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US6703422B2 (en) 2000-10-11 2004-03-09 Esperion Therapeutics, Inc. Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US6713507B2 (en) 2000-10-11 2004-03-30 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
WO2004067489A2 (en) 2003-01-23 2004-08-12 Esperion Therapeutics, Inc. Hydroxyl compounds and compositions for cholesterol management and related uses
EP1701931B1 (en) 2003-12-24 2018-10-10 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
WO2005062718A2 (en) * 2003-12-30 2005-07-14 Syndromex Ltd. Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid
CA2617213C (en) 2005-07-29 2014-01-28 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
KR101444489B1 (ko) 2007-02-01 2014-09-24 리스버로직스 코퍼레이션 심혈관 질환을 예방 및 치료하기 위한 화합물
IL181577A0 (en) * 2007-02-26 2007-07-04 Jacob Bar Tana Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
CA2688111A1 (en) 2007-05-23 2008-12-04 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
WO2009158404A1 (en) 2008-06-26 2009-12-30 Resverlogix Corp. Methods of preparing quinazolinone derivatives
WO2010079431A2 (en) 2009-01-08 2010-07-15 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
KR101803259B1 (ko) 2009-03-18 2017-11-30 리스버로직스 코퍼레이션 신규한 소염제
CN107252429B (zh) 2009-04-22 2023-06-16 雷斯韦洛吉克斯公司 新抗炎剂
EP3358008A1 (en) 2009-09-03 2018-08-08 Pfizer Vaccines LLC Pcsk9 vaccine
BR112013008675A2 (pt) 2010-09-20 2016-06-21 Kareus Therapeutics Sa métodos e composições para o tratamento de diabetes e dislipidemia
EP2680883B1 (en) 2011-03-02 2018-09-05 Pfizer Inc Pcsk9 vaccine
DK2773354T3 (da) 2011-11-01 2019-08-05 Resverlogix Corp Oralformuleringer med øjeblikkelig frigivelse for substituerede quinazolinoner
US10479752B2 (en) * 2011-12-08 2019-11-19 Syndromex Ltd. Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
KR102662814B1 (ko) 2015-03-13 2024-05-03 리스버로직스 코퍼레이션 보체 관련 질환을 치료하기 위한 조성물 및 치료 방법
MA42616A (fr) 2015-03-13 2021-05-19 Esperion Therapeutics Inc Combinaisons et formulations de doses fixes comprenant etc1002 et ézétimibe, et procédés de traitement ou de réduction du risque de maladie cardio-vasculaire
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CN107118098B (zh) * 2016-02-25 2020-07-14 中国科学院上海药物研究所 一类脂肪酸类化合物、其制备方法及其用途
EP3463330B1 (en) * 2016-06-02 2022-05-04 Syndromex Ltd. Diabetes treatment regimens using alpha, alpha-substituted long-chain amphipathic carboxylates
US10512624B2 (en) 2016-11-30 2019-12-24 Syndromex Ltd. Long-chain amphipathic dicarboxylic acids for treatment of diabetes type-1
CA3144372A1 (en) 2019-06-21 2020-12-24 Esperion Therapeutics, Inc. Salt forms of bempedoic acid and methods for using the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268082A (en) 1969-08-08 1972-03-22 Orsymonde Improvements in or relating to bis-(carboxy-alkylene-thio)-decanes
US3930024A (en) * 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
BE755550A (fr) * 1969-09-02 1971-02-01 Parke Davis & Co Acides alcanedioiques, leurs sels et leurs esters abaissant la teneur en triglycerides du serum sanguin
FR2288516A2 (fr) 1974-10-21 1976-05-21 Orsymonde Nouveaux bis-(carboxyalcoylene-thio)-1,10 decanes et leurs derives
IL64542A0 (en) * 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4634975A (en) * 1984-09-17 1987-01-06 Progressive Dynamics, Inc. Method and apparatus for producing electromagnetic surveillance fields
JPS61171417A (ja) * 1985-01-23 1986-08-02 Wakunaga Seiyaku Kk 抗糖尿病剤
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3634356A1 (de) * 1986-10-08 1988-04-21 Epis Sa Arzneimittel enthaltend alpha-halogenierte dicarbonsaeuren
DE4224670A1 (de) * 1992-07-25 1994-01-27 Boehringer Mannheim Gmbh Verwendung von â,w-Dicarbonsäuren als Fibrinogensenker
US5648387A (en) * 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
IL119971A (en) * 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
JP2003001549A (ja) * 2001-06-26 2003-01-08 Howa Mach Ltd 光電式刃具折れ検知装置

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods

Also Published As

Publication number Publication date
KR20000069934A (ko) 2000-11-25
AU742945B2 (en) 2002-01-17
EP0988274B1 (en) 2009-05-20
IL119971A0 (en) 1997-04-15
EP2112134B1 (en) 2013-10-30
EP0988274A4 (en) 2000-10-18
KR20070026888A (ko) 2007-03-08
KR100806928B1 (ko) 2008-02-22
AU7994798A (en) 1998-08-03
IL119971A (en) 2003-02-12
US20020049345A1 (en) 2002-04-25
JP5479857B2 (ja) 2014-04-23
US6284903B1 (en) 2001-09-04
ATE431816T1 (de) 2009-06-15
US20040132818A1 (en) 2004-07-08
CA2277075C (en) 2010-06-22
JP2001507713A (ja) 2001-06-12
WO1998030530A1 (en) 1998-07-16
EP0988274A1 (en) 2000-03-29
US6800772B2 (en) 2004-10-05
DE69739415D1 (de) 2009-07-02
EP2112134A1 (en) 2009-10-28
JP2010077141A (ja) 2010-04-08
CA2277075A1 (en) 1998-07-16

Similar Documents

Publication Publication Date Title
KR100806927B1 (ko) 카르복실산, 그의 유도체 및 이들을 함유하는 약학적조성물
US4634795A (en) Long-chain α,ω-di-carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
IE49902B1 (en) 4-substituted-3-hydroxy-3-pyrroline-2,5-dione compounds,process for their preparation and pharmaceutical compositions containing the same
JPH0112727B2 (enExample)
US6245814B1 (en) Diphenylethylene compounds
AU778767B2 (en) Novel diphenylethylene compounds
WO2016015479A1 (zh) β-榄香烯13位衍生物及其治疗动脉粥样硬化的用途
JPH0120127B2 (enExample)
JPH0432073B2 (enExample)
EP2226329B1 (en) Metal-containing platensimycin analogues
JPH0729923B2 (ja) カスタノスペルミン抗糖尿病剤
AU780162B2 (en) Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JP2954989B2 (ja) ビスフェノール誘導体での真性糖尿病処置法
WO2003099269A1 (en) Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease
MXPA99006358A (en) Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
DE2151720A1 (de) Arzneimittel zur Bekaempfung von Virusinfektionen und seine Verwendung als Zusatz zu Tierfutterkonzentraten
US4457941A (en) Use of pyrrolo-pyrrole in treating microvascular diseases associated with diabetes
SU1015622A1 (ru) 2-Замещенные 3-окси-5-метил-4-тиофенуксусные кислоты,обладающие противовоспалительной и анальгетической активностью и способ их получени
DE2430077A1 (de) Derivate von phenylessigsaeure, verfahren zu ihrer herstellung und sie enthaltende arzneimittelzubereitungen
JPH072675B2 (ja) 鎌状赤血球貧血の治療に有用な化合物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20110714

Year of fee payment: 4

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20120219

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120219

St.27 status event code: N-4-6-H10-H13-oth-PC1903

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000